[Featured Stock] Jinwon Life Sciences Shares Rise on News of Plasmid DNA Supply to the US
Jinwon Life Sciences is showing a sharp rise in the stock market on the 30th. Expectations for improved performance have increased as it has decided to consecutively supply plasmid DNA to U.S. biotech companies.
As of 10:25 a.m., Jinwon Life Sciences is trading at 2,635 KRW, up 15.57% from the previous day's closing price. It rose relatively steeply from the beginning of the session and then slightly corrected after reaching a peak of 2,820 KRW.
Jinwon Life Sciences announced that it signed a supply contract for plasmid DNA worth 2.7 million USD (approximately 3.5 billion KRW) with a U.S. biotech company on the same day. Plasmid DNA is a key raw material for developing cell and gene therapies, and demand has been increasing recently as the development of cell and gene therapies expands.
Hot Picks Today
Why Didn't My Loan Interest Rate Drop Even After Regular Salary Transfers?… FSS Says "Check This"
- Seoul Tops London and Tokyo for the First Time... Foreign Media: "Seoul Is Becoming the New Paris"
- "Lost Vision After Wegovy and Ozempic: U.S. Patients File Lawsuits Over Sudden Sight Loss While Trying to Lose Weight"
- "Is the YouTuber Telling the Truth?" 300,000 Views in One Day... The Real Story Behind Shin Ramyun's Flavor, According to Nongshim [Tastelovers X-File]
On the 24th, Jinwon Life Sciences also signed a contract to supply plasmid DNA worth 3.62 million USD (approximately 5 billion KRW) to a U.S. company. As the supply of plasmid DNA continues to expand, expectations for improved performance are growing.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
